Semaglutide for Health & Longevity

Evidence Review created on 10/31/2026 using AI4L + evidence-mcp / Opus 5.5

Also known as: Ozempic, Wegovy, Rybelsus, NN9535, NNC 0113-0217

Motivation

Semaglutide is a prescription medicine, given as a weekly injection or a daily oral medication, that copies a natural gut hormone released after meals to signal fullness and help control blood sugar. Sold as Ozempic, Wegovy and Rybelsus, it has become one of the most widely used medicines in the world for diabetes and weight loss. Longevity-minded adults are interested because it has been studied for effects on the heart and on survival, not only on body weight.

Large, multi-year trials have tested whether it changes the rates of heart attacks, strokes and deaths rather than body weight alone. Questions about muscle loss, side effects and what happens after stopping have drawn equally close scrutiny, and a recent study in aging mice asked whether it might slow aging itself.

This review examines the evidence for and against semaglutide use by health-conscious adults seeking more years of healthy life. It covers expected benefits, risks and side effects, interactions, dosing protocols, monitoring and ongoing research, with attention to who was studied and who paid for the studies.

Benefits - Risks - Protocol - Conclusion

Expert commentary on semaglutide, a GLP-1 receptor agonist (a drug that mimics glucagon-like peptide-1, a gut hormone that signals fullness and stimulates insulin release), from longevity-focused physicians and organizations.

FoundMyFitness covers semaglutide in a free clip, Rethinking GLP-1 Drugs for Weight Loss and Long-Term Health (Rhonda Patrick with Ben Bikman); it is not listed above because the five-item limit was filled by the other priority sources.

Grokipedia

Semaglutide

An AI-written encyclopedia overview of semaglutide’s chemistry, approvals, trial history and safety debates; useful for orientation, though individual claims are best checked against the primary studies.

Examine

No Examine article on semaglutide exists. Examine.com does not typically cover prescription medications.

ConsumerLab

Supplements to Take or Avoid When Using a GLP-1 Drug

Addresses supplements relevant during semaglutide and other GLP-1 drug use, including protein, fiber, vitamin B12, iron, potassium and blood-sugar-lowering products; full details are members-only.

Systematic Reviews

Systematic reviews and meta-analyses of semaglutide covering survival and overall safety, weight loss in obesity, eye risks, pancreatitis and lean mass.

Mechanism of Action

Semaglutide, a modified human GLP-1 with 94% sequence similarity, selectively activates the GLP-1 receptor, per the Food and Drug Administration (FDA) prescribing information (Wegovy FDA label). A position-8 amino-acid substitution protects it from DPP-4 (dipeptidyl peptidase-4, the enzyme that inactivates natural GLP-1), and an attached fatty-acid chain binds it to albumin (the main blood protein), a design reported by chemists at the manufacturer, Novo Nordisk (Lau 2015).

  • Appetite and food reward: Activation in brain appetite centers reduces hunger, cravings and calorie intake; weight loss comes mainly from eating less.
  • Glucose control: It raises insulin and lowers glucagon (a blood-sugar-raising hormone) only when glucose is elevated, limiting hypoglycemia (low blood glucose) when used alone.
  • Stomach emptying: Slower emptying adds fullness and causes most gastrointestinal side effects.
  • Weight-independent effects (debated): Lower inflammation, blood pressure and atherosclerotic (artery-clogging) plaque activity may explain cardiovascular benefit beyond weight loss; a competing view attributes most benefit to weight and glucose reduction, which current trials cannot separate.

Key pharmacological properties:

  • Half-life: About one week; the drug circulates 5–7 weeks after the last dose (Wegovy FDA label).
  • Distribution: Over 99% albumin-bound, with limited tissue distribution; bioavailability (share of a dose reaching the blood) 89% for under-the-skin injection, 1–2% for tablets using SNAC (an absorption enhancer).
  • Metabolism: Breakdown of the peptide chain and fatty-acid side chain; no cytochrome P450 (liver drug-metabolizing enzyme) pathway, hence few pharmacokinetic interactions (changes in drug absorption or clearance), per a systematic review (Yang 2024).

Historical Context & Evolution

Semaglutide descends from exenatide, a GLP-1-like peptide found in Gila monster saliva, and from Novo Nordisk’s once-daily liraglutide. It was engineered as a once-weekly diabetes drug (Lau 2015). Its first major outcome trial, the manufacturer-funded SUSTAIN-6, found fewer cardiovascular events but more retinopathy complications in type 2 diabetes (Marso 2016), and the FDA approved it for type 2 diabetes as Ozempic and as oral Rybelsus (Rybelsus FDA label, Ozempic FDA label).

Interest from health optimizers began with weight: STEP 1 reported about 15% weight loss in adults without diabetes (Wilding 2021), leading to approval for weight management as Wegovy (Wegovy FDA label). The question then shifted to hard outcomes. SELECT tested cardiovascular events in people with obesity but without diabetes (Lincoff 2023), followed by an FDA cardiovascular indication (FDA announcement). Kidney, liver, heart failure and arthritis trials followed, and the Wegovy label now includes MASH (metabolic dysfunction-associated steatohepatitis, inflammatory fatty liver disease) and a 25 mg tablet (Wegovy FDA label).

Opinion has not moved in one direction. Observational signals of dementia protection were followed by negative trials in early Alzheimer’s disease (Cummings 2026), later summarized in a review by the trial leaders (Cummings 2026). A suicidality warning was removed from the US label in 2026 (Wegovy FDA label), while the EMA (European Medicines Agency) added NAION as a very rare side effect (EMA safety committee review). A 2026 mouse lifespan study (Feng 2026) renewed interest in semaglutide as an aging intervention.

Expected Benefits

Nearly all outcome trials below were funded by the manufacturer, Novo Nordisk, and co-authored by its employees; independent analyses are identified where they exist.

High 🟩 🟩 🟩

Body Weight and Fat Reduction

Semaglutide produces large, sustained weight loss, mostly fat, by reducing appetite. This has been replicated in STEP trials led by Wilding (adults without diabetes), Davies (type 2 diabetes) and Garvey (two years), and in an oral-tablet trial led by Wharton (Wilding 2021, Davies 2021, Garvey 2022, Wharton 2025). An independent meta-analysis from McGill (Moiz) confirms durability beyond 68 weeks (Moiz 2024). Loss is smaller with type 2 diabetes.

Magnitude: 14.9% versus 2.4% body-weight loss at 68 weeks, a difference of 12.4 percentage points (95% confidence interval [CI, the range likely to contain the true effect] −13.4 to −11.5) (Wilding 2021).

Fewer Heart Attacks, Strokes and Cardiovascular Deaths

Semaglutide lowered major adverse cardiovascular events (cardiovascular death, nonfatal heart attack or nonfatal stroke) in three placebo-controlled outcome trials led by Lincoff (SELECT, obesity without diabetes), Marso (SUSTAIN-6, type 2 diabetes) and McGuire (SOUL, oral 14 mg in type 2 diabetes) (Lincoff 2023, Marso 2016, McGuire 2025). All participants had established cardiovascular disease or high risk, so the evidence covers secondary rather than primary prevention.

Magnitude: 6.5% versus 8.0% had an event over about 40 months; hazard ratio (HR, the relative event rate versus placebo) 0.80 (95% CI 0.72 to 0.90) (Lincoff 2023).

Lower All-Cause Mortality

An independent meta-analysis of 50 placebo-controlled trials (Sillassen, Copenhagen Trial Unit) found fewer deaths from any cause, with high-certainty evidence (Sillassen 2025). Individual trials led by Scirica (SELECT, fewer non-cardiovascular and infection deaths; the cardiovascular-death reduction was not significant) and Perkovic (FLOW, chronic kidney disease with type 2 diabetes) agree (Scirica 2024, Perkovic 2024). Participants had obesity, diabetes or cardiovascular disease; no mortality data exist for metabolically healthy adults.

Magnitude: Relative risk (RR, risk versus placebo) 0.85 (95% CI 0.79 to 0.91) across 54,972 participants (Sillassen 2025); in SELECT, HR 0.81 (95% CI 0.71 to 0.93) (Scirica 2024).

Kidney Protection ⚠️ Conflicted

In FLOW (Perkovic; type 2 diabetes with chronic kidney disease), semaglutide reduced kidney failure, major decline in eGFR (estimated glomerular filtration rate, a measure of kidney filtration) and kidney or cardiovascular death (Perkovic 2024). SELECT’s prespecified kidney analysis (Colhoun) found a similar reduction in obesity without diabetes (Colhoun 2024). In SOUL, oral semaglutide did not significantly reduce major kidney events, a confirmatory secondary outcome (McGuire 2025). Net reading: injectable semaglutide slows kidney decline in diabetic kidney disease and obesity, while the oral null result limits generalization.

Magnitude: Major kidney disease events 331 versus 410 first events, HR 0.76 (95% CI 0.66 to 0.88); eGFR declined 1.16 mL/min/1.73 m² per year more slowly than with placebo (95% CI 0.86 to 1.47) (Perkovic 2024).

Blood Glucose Control and Fewer New Cases of Type 2 Diabetes

Semaglutide lowers HbA1c (average blood glucose over about three months) in type 2 diabetes more than placebo and comparator drugs, pooled independently by Andreadis (Thessaloniki) and Eisa (Fresno) (Andreadis 2018, Eisa 2026). In obesity without diabetes, it returned more people to normal glucose and cut new diabetes in STEP 10 (McGowan; prediabetes, glucose above normal but below the diabetes threshold) and SELECT (Kahn) (McGowan 2024, Kahn 2024). In SELECT, HbA1c later rose at a similar pace in both groups, so the drug lowered glucose rather than slowing its long-term rise.

Magnitude: HbA1c 1.01 (95% CI 0.56 to 1.47) and 1.38 (95% CI 1.05 to 1.70) percentage points lower than placebo with 0.5 mg and 1 mg weekly (Andreadis 2018); return to normal blood glucose at 52 weeks in 81% versus 14% with placebo, odds ratio (OR, the relative odds versus placebo) 19.8 (95% CI 8.7 to 45.2) (McGowan 2024); new diabetes (HbA1c 6.5% or higher) by week 156 in 1.5% versus 6.9% with placebo (Kahn 2024).

Lower Blood Pressure

Semaglutide lowers systolic blood pressure in the STEP 4 trial led by Rubino and in diabetes trials from several groups pooled by Andreadis (Rubino 2021, Andreadis 2018). The reduction is modest compared with blood-pressure medicines and reverses toward baseline within a year of stopping (Wilding 2022).

Magnitude: Systolic blood pressure 3.9 mm Hg lower with continued semaglutide than after switching to placebo (95% CI −5.8 to −2.0) over 48 weeks (Rubino 2021).

Reduced Alcohol Intake and Craving ⚠️ Conflicted

In randomized trials in alcohol use disorder from three independent groups, semaglutide reduced heavy drinking days or alcohol consumed: Klausen (26 weeks, 108 adults with obesity), Hendershot (9 weeks, 48 adults, low dose) and Schacht (8 weeks, 50 adults, oral tablets) (Klausen 2026, Hendershot 2025, Schacht 2026). Hendershot found no change in average drinks per day or drinking days; Schacht none in drinks per day or laboratory craving, its primary endpoint. Net reading: heavy drinking falls consistently in these small, short trials; effects on overall intake and craving are inconsistent.

Magnitude: Heavy drinking days fell 13.7 percentage points more than with placebo (95% CI 5.4 to 22.0) over 26 weeks (Klausen 2026); alcohol consumed in a laboratory session: standardized effect (β, a regression-based effect size) −0.48 versus placebo (95% CI −0.85 to −0.11) (Hendershot 2025).

Medium 🟩 🟩

Fewer Heart Failure Events and Better Heart Failure Symptoms

In STEP-HFpEF (Kosiborod), semaglutide 2.4 mg improved symptoms, physical limitation and walking distance in HFpEF (heart failure with preserved ejection fraction, a stiff-heart form of heart failure) with obesity, and lowered CRP (C-reactive protein, an inflammation marker) by 43.5% versus 7.3% (Kosiborod 2023). A meta-analysis by Barbagelata of six randomized trials and two cohorts found fewer heart failure events (Barbagelata 2024). The trials come from a single manufacturer-funded program.

Magnitude: Kansas City Cardiomyopathy Questionnaire clinical summary score (a 0–100 heart-failure symptom scale) 7.8 points more improvement than placebo (95% CI 4.8 to 10.9); 6-minute walk distance 20.3 m more (95% CI 8.6 to 32.1) (Kosiborod 2023); heart failure events OR 0.74 (95% CI 0.58 to 0.94) versus placebo or control (Barbagelata 2024).

Liver Inflammation and Scarring in MASH

In ESSENCE (Sanyal and Newsome), 72 weeks of semaglutide 2.4 mg resolved steatohepatitis (fatty-liver inflammation) and reduced fibrosis (liver scarring) on biopsy more often than placebo in MASH with moderate-to-advanced fibrosis (Sanyal 2025). This single trial underpins the accelerated approval (Wegovy FDA label). Whether biopsy gains translate into less cirrhosis (advanced liver scarring) awaits part 2 of the trial.

Magnitude: Steatohepatitis resolution 62.9% versus 34.3% (difference 28.7 percentage points, 95% CI 21.1 to 36.2); fibrosis improvement 36.8% versus 22.4% (difference 14.4 percentage points, 95% CI 7.5 to 21.3) (Sanyal 2025).

Walking Capacity in Peripheral Artery Disease

In STRIDE (Bonaca), semaglutide 1 mg weekly increased maximum treadmill walking distance in people with type 2 diabetes and peripheral artery disease (narrowed leg arteries) causing intermittent claudication (leg pain on walking) (Bonaca 2025). It is a single manufacturer-funded trial, and effects in people without diabetes are untested.

Magnitude: Maximum walking distance ratio to baseline 1.21 versus 1.08; estimated treatment ratio 1.13 (95% CI 1.06 to 1.21) (Bonaca 2025).

Fewer New Cases of Atrial Fibrillation

A meta-analysis by Saglietto of ten placebo-controlled trials found fewer new cases of atrial fibrillation (an irregular heart rhythm that raises stroke risk) with semaglutide (Saglietto 2024). Atrial fibrillation was recorded as an adverse event rather than a planned outcome, and the pooled trials share one sponsor, so the finding rests on a single trial program.

Magnitude: RR 0.58 (95% CI 0.40 to 0.85) versus placebo across 12,651 patients (Saglietto 2024).

Modest LDL Cholesterol Reduction

Semaglutide modestly lowers LDL (low-density lipoprotein, the main artery-clogging cholesterol carrier) and total cholesterol in type 2 diabetes, according to an independent network meta-analysis (comparing many drugs within one analysis) of 76 trials by Yao (Beijing University of Chinese Medicine) (Yao 2024). The semaglutide trials it pooled come largely from one manufacturer-funded program, and the reduction is small compared with cholesterol-lowering drugs.

Magnitude: LDL cholesterol 0.16 mmol/L lower than placebo (95% CI 0.02 to 0.30) and total cholesterol 0.48 mmol/L lower (95% CI 0.11 to 0.84) (Yao 2024).

Knee Osteoarthritis Pain ⚠️ Conflicted

In STEP 9 (Bliddal), a single manufacturer-funded trial, semaglutide reduced knee osteoarthritis pain and improved physical function in obesity (Bliddal 2024). A meta-analysis across GLP-1 drugs found no significant pain change, but it is class-level (indirect: not semaglutide-specific) (Beaudart 2026). Net reading: the semaglutide-specific trial shows a benefit that likely tracks substantial weight loss.

Magnitude: WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index, 0–100) pain score fell 41.7 points versus 27.5 with placebo; between-group difference −14.1 points (95% CI −20.0 to −8.3) (P<0.001, a statistically significant difference) (Bliddal 2024).

Better Physical Functioning and Quality of Life

Semaglutide modestly improves self-rated physical functioning and quality of life on the SF-36 (Short Form-36, a validated health-status questionnaire), likely through weight loss. This was shown in STEP 4 led by Rubino and in pooled analyses by Eisa (Fresno) and the World Health Organization-funded Cochrane review led by Bracchiglione (Rubino 2021, Eisa 2026, Bracchiglione 2025). Cochrane judged the gain too small to be clinically meaningful, and the pooled trials come largely from one manufacturer-funded program.

Magnitude: SF-36 physical functioning score 2.12 points higher than placebo at 6 to 17 months (95% CI 0.95 to 3.28) (Bracchiglione 2025); 2.5 points higher with continued semaglutide than after switching to placebo (95% CI 1.6 to 3.3) (Rubino 2021).

Low 🟩

Lower Obesity-Associated Cancer Risk ⚠️ Conflicted

In US health records, GLP-1 drug users with type 2 diabetes had fewer obesity-associated cancers than insulin users, not metformin users (class-level, observational; indirect: not semaglutide-specific) (Wang 2024). A meta-analysis of 37 randomized trials found no cancer difference versus placebo (Nagendra 2023). Net reading: no cancer reduction is established.

Magnitude: Colorectal cancer HR 0.54 (95% CI 0.46 to 0.64) and pancreatic cancer HR 0.41 (95% CI 0.33 to 0.50) versus insulin; no reduction versus metformin (Wang 2024); all neoplasms OR 0.95 (95% CI 0.62 to 1.45) versus placebo in randomized trials (Nagendra 2023).

Lower Dementia Risk ⚠️ Conflicted

In US health-record analyses mimicking randomized trials, semaglutide users with type 2 diabetes had fewer first Alzheimer’s diagnoses than users of other diabetes drugs (Wang 2024). The EVOKE trials showed no benefit but treated established early Alzheimer’s disease, not prevention (Cummings 2026). Net reading: prevention is unproven.

Magnitude: First Alzheimer’s diagnosis HR 0.33 (95% CI 0.21 to 0.51) versus insulin and 0.59 (95% CI 0.37 to 0.95) versus other GLP-1 drugs (Wang 2024).

Speculative 🟨

Slower Biological Aging and Longer Lifespan

Late-life semaglutide extended female mouse lifespan (Feng 2026). An unplanned trial analysis in people with HIV (human immunodeficiency virus) reported slower epigenetic clocks, unvalidated DNA-methylation age estimates (Corley 2026). No human aging-outcome data exist.

Benefit-Modifying Factors

  • Genetics: A GLP1R (the gene encoding the GLP-1 receptor) variant added 0.76 kg weight loss per copy in a self-reported study of 27,885 GLP-1 drug users (Su 2026) and faster loss in 112 semaglutide users (Phan 2025); no validated genetic test guides use.
  • Baseline biomarkers: Higher baseline weight, HbA1c and blood pressure allow larger absolute reductions; cardiovascular, kidney and mortality benefits were shown in people with established disease, not in lean, metabolically healthy adults (Lincoff 2023).
  • Sex: Women made up a minority of SELECT participants (Lincoff 2023), which limits sex-specific estimates of cardiovascular benefit. Women lost weight faster than men in a semaglutide cohort, with sex an independent predictor (Phan 2025).
  • Type 2 diabetes: Weight loss is smaller with diabetes: 9.6% versus 3.4% with placebo in STEP 2 (Davies 2021), compared with 14.9% versus 2.4% without diabetes in STEP 1 (Wilding 2021).
  • Pre-existing organ disease: People with MASH, chronic kidney disease, HFpEF, peripheral artery disease or knee osteoarthritis have documented organ-specific benefits; those without these conditions cannot expect them.
  • Age: Older adults show cardiometabolic benefits, but trials included few participants over 75 (Wegovy FDA label), and lean-mass loss weighs more heavily as frailty approaches.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Gastrointestinal Adverse Events

Nausea, vomiting, diarrhea and constipation are the most common effects, driven by slowed stomach emptying and peaking during dose escalation; most are mild to moderate. This was replicated in an independent meta-analysis (Sillassen) and in STEP trials led by Wilding (Sillassen 2025, Wilding 2021). The label also lists severe reactions, ileus (stalled bowel movement), intestinal obstruction and acute kidney injury from fluid loss (Wegovy FDA label).

Magnitude: Nausea 44% versus 16% with placebo, vomiting 24% versus 6%, diarrhea 30% versus 16% (Wegovy FDA label); nausea RR 3.00 (95% CI 2.63 to 3.42) (Sillassen 2025); treatment stopped for gastrointestinal events in 4.5% versus 0.8% (Wilding 2021).

Gallbladder Disease

Rapid weight loss and reduced gallbladder emptying favor gallstones (cholelithiasis) and cholecystitis (gallbladder inflammation). An independent meta-analysis from Marshfield Clinic (Kommu) of nine trials led by different groups, including Wilding and Garvey, found more gallbladder disorders and gallstones (Kommu 2024); the label reports the same pattern (Wegovy FDA label).

Magnitude: Gallstones 1.6% versus 0.7% with placebo and cholecystitis 0.6% versus 0.2% (Wegovy FDA label); gallstones OR 2.06, CI not reported in the abstract (Kommu 2024).

Weight and Metabolic Rebound After Stopping

Stopping semaglutide is followed by regain of most lost weight and reversal of cardiometabolic improvements. This was shown in STEP 4 (Rubino) and the STEP 1 extension (Wilding) and pooled by an independent meta-analysis from Taiwan (Tzang; indirect: GLP-1 drugs as a class, not semaglutide-specific) (Rubino 2021, Wilding 2022, Tzang 2025). Sustained benefit therefore depends on continued use.

Magnitude: After switching to placebo, weight rose 6.9% versus a further 7.9% loss with continued drug (difference 14.8 percentage points, 95% CI 13.5 to 16.0) (Rubino 2021); one year after stopping, former semaglutide users regained 11.6 versus 1.9 percentage points for former placebo users, not compared between groups (Wilding 2022).

Fatigue, Dizziness and Headache

Fatigue (including weakness), dizziness and headache are among the most common effects outside the digestive tract; most are mild, and reduced food and fluid intake may contribute, though the mechanism is not established. This was shown in an independent meta-analysis (Sillassen, Copenhagen Trial Unit) and in the manufacturer’s pooled weight-management trials summarized in the label (Sillassen 2025, Wegovy FDA label).

Magnitude: Fatigue 11% versus 5% with placebo, headache 14% versus 10%, dizziness 8% versus 4% (Wegovy FDA label); fatigue RR 1.67 (95% CI 1.41 to 1.97), dizziness RR 1.49 (95% CI 1.18 to 1.87) and headache RR 1.19 (95% CI 1.05 to 1.36) versus placebo (Sillassen 2025).

Medium 🟥 🟥

Lean Mass Loss

Part of the weight lost is lean tissue, including muscle, measured by DXA (dual-energy X-ray absorptiometry, a body-composition scan). A semaglutide-specific systematic review (Bikou) and a GLP-1 class meta-analysis (Beaudart, low certainty) agree (Bikou 2024, Beaudart 2026). Whether this impairs strength or function is unknown; the concern is greatest in older adults.

Magnitude: Lean mass accounted for roughly 0% to 40% of total weight lost across six studies, a share of the loss rather than a between-group difference (Bikou 2024).

NAION (Optic-Nerve Stroke) ⚠️ Conflicted

NAION causes sudden, usually painless and often permanent vision loss in one eye. A trial meta-analysis (Natividade), a matched cohort (Hathaway) and a large claims study of GLP-1 drugs as a class (Tesfaye; indirect: not semaglutide-specific) found higher risk (Natividade 2025, Hathaway 2024, Tesfaye 2026). A meta-analysis of six observational studies found no consistent overall increase (Abdelaal 2026). The EMA classifies it as a very rare side effect (EMA safety committee review). Net reading: a small excess risk is likely, chiefly in type 2 diabetes, with low absolute risk.

Magnitude: 36-month cumulative incidence (share affected over the period) 8.9% versus 1.8%, HR 4.28 (95% CI 1.62 to 11.29), in a neuro-ophthalmology referral cohort with type 2 diabetes (Hathaway 2024); in claims data for GLP-1 drugs as a class, HR 1.85 (95% CI 1.51 to 2.27), rate difference 0.29 per 1,000 person-years (one person-year is one person treated for one year) versus SGLT2 inhibitors (glucose-lowering drugs that make the kidneys excrete sugar) (Tesfaye 2026).

Low Blood Glucose With Insulin or Sulfonylureas

Hypoglycemia becomes more likely when semaglutide is combined with insulin or sulfonylureas (oral drugs that force insulin release, such as glipizide and glimepiride); the label advises considering lower doses of those drugs (Wegovy FDA label). Used without them, semaglutide did not increase hypoglycemia in a meta-analysis of diabetes trials (Andreadis 2018).

Magnitude: Hypoglycemia in type 2 diabetes 6% versus 2% with placebo in Wegovy weight-management trials (Wegovy FDA label).

Hair Loss

Hair loss is more frequent with semaglutide than with placebo in controlled trials (Wegovy FDA label). A systematic review found it dose-dependent and more common in women, with telogen effluvium (temporary shedding after rapid weight loss) and androgenetic (pattern) hair loss the predominant subtypes (Gupta 2026).

Magnitude: Hair loss 3% versus 1% with placebo in weight-management trials (Wegovy FDA label).

Skin Sensitivity (Dysesthesia) at High Dose

Dysesthesia (abnormal skin sensations such as burning, tingling or sensitivity) was common with the 7.2 mg dose in STEP UP (Wharton) and much less frequent at 2.4 mg (Wharton 2025). The mechanism is unknown, and the evidence comes from a single trial.

Magnitude: 22.9% with 7.2 mg versus 6.0% with 2.4 mg and 0.5% with placebo (Wharton 2025).

Higher Resting Heart Rate

Semaglutide raises resting heart rate by a few beats per minute, a class effect of GLP-1 drugs; heart rate was also assessed in a meta-analysis of diabetes trials (Wegovy FDA label, Andreadis 2018). Its clinical significance is unclear given the cardiovascular outcome benefits.

Magnitude: Mean increase of 1 to 4 beats per minute versus placebo; maximum increases of 20 beats per minute or more in 26% versus 16% (Wegovy FDA label).

Hip and Pelvic Fractures in Women and Older Adults

The label reports more hip and pelvic fractures with semaglutide than placebo in women and in adults 75 and older in the SELECT cardiovascular trial (Wegovy FDA label). The signal comes from a single trial, and its mechanism is not established. A meta-analysis across GLP-1 drugs found no overall effect on fractures or bone density, but is indirect, not semaglutide-specific (Beaudart 2026).

Magnitude: Hip or pelvic fractures in women 1% versus 0.2% with placebo, and in adults 75 and older 2.4% versus 0.6% (Wegovy FDA label).

Low Blood Pressure and Fainting

Hypotension (abnormally low blood pressure) and syncope (fainting) were reported more often with semaglutide than placebo in the manufacturer’s pooled weight-management trials, partly from fluid loss with gastrointestinal effects and more often in people taking antihypertensive (blood-pressure-lowering) drugs (Wegovy FDA label). An individual-patient meta-analysis of three trials (Kennedy, Trinity College Dublin) found systolic pressure 4.95 mm Hg lower than placebo, with antihypertensive treatment reduced more often (Kennedy 2024). The data come from one manufacturer’s trial program.

Magnitude: Hypotension-related adverse reactions in 1.3% versus 0.4% with placebo, and syncope in 0.8% versus 0.2% (Wegovy FDA label).

Appendicitis

Appendicitis (inflammation of the appendix), including perforated cases, occurred more often with semaglutide than placebo in the manufacturer’s weight-management trials (Wegovy FDA label). A case report described appendicitis requiring surgery months after starting semaglutide and proposed its gastrointestinal effects as a possible contributor (Casella 2024). Numbers are small, the mechanism is unproven, and the trials come from one manufacturer’s program.

Magnitude: Appendicitis in 0.5% versus 0.2% with placebo (10 versus 2 patients) in weight-management trials (Wegovy FDA label).

Kidney Stones

Kidney stones (urolithiasis) were reported more often with semaglutide than placebo in the SELECT cardiovascular trial, including serious cases (Wegovy FDA label); lower fluid intake may contribute, but the mechanism is not established. A single-center cohort of prior stone formers taking semaglutide or tirzepatide (indirect: partly another drug) found new stone episodes in about one in ten, without a comparison group (Danau 2026). The signal rests on one trial.

Magnitude: Kidney stones in 1.2% versus 0.8% with placebo, serious cases 0.6% versus 0.4% (Wegovy FDA label); stone recurrence in 10.3% of prior stone formers over a median of 9 months, no control group (Danau 2026).

Injection Site Reactions

Itching, redness, inflammation, hardening or irritation at the injection site occurred slightly more often with semaglutide than placebo in the manufacturer’s weight-management trials (Wegovy FDA label). In a head-to-head trial in type 2 diabetes, such reactions were far less frequent than with another weekly injectable GLP-1 drug (Ahmann 2018). Reactions are usually mild and local; the data come from one manufacturer’s trial program.

Magnitude: Injection site reactions in 1.4% versus 1% with placebo (Wegovy FDA label); 1.2% with semaglutide versus 22.0% with exenatide extended release (Ahmann 2018).

Taste Disturbance (Dysgeusia)

Dysgeusia (altered or unpleasant taste) was reported more often with semaglutide than placebo in the manufacturer’s weight-management trials (Wegovy FDA label). An analysis of the FDA adverse event reporting system found a disproportionate reporting signal for dysgeusia with semaglutide (Khan 2025). The mechanism is unknown, and trial data come from one manufacturer’s program.

Magnitude: Dysgeusia in 1.7% versus 0.5% with placebo in weight-management trials (Wegovy FDA label).

Low 🟥

Diabetic Retinopathy Complications ⚠️ Conflicted

In SUSTAIN-6, retinopathy complications were more frequent with semaglutide, possibly from rapid glucose lowering (Marso 2016). A 78-trial meta-analysis found no overall increase (Natividade 2025). Net reading: risk appears confined to pre-existing advanced retinopathy.

Magnitude: SUSTAIN-6 HR 1.76 (95% CI 1.11 to 2.78) versus placebo (Marso 2016); meta-analysis OR 1.04 (95% CI 0.92 to 1.17) (Natividade 2025).

Acute Pancreatitis ⚠️ Conflicted

The label warns of acute pancreatitis, including fatal cases, with GLP-1 drugs (Wegovy FDA label). A meta-analysis of 21 placebo-controlled trials found no increase (Masson 2024). Net reading: any excess risk is small.

Magnitude: OR 0.7 (95% CI 0.5 to 1.2) versus placebo across 34,721 patients (Masson 2024).

Thyroid C-Cell Tumors ⚠️ Conflicted

Semaglutide causes thyroid C-cell (calcitonin-producing cell) tumors in rodents, the basis of a boxed warning (Wegovy FDA label). Class-level human data conflict (Bezin 2023, Pasternak 2024), possibly reflecting different comparator drugs and closer thyroid surveillance of treated patients. Net reading: no confirmed human excess.

Magnitude: French case-control study: thyroid cancer HR 1.58 (95% CI 1.27 to 1.95) after 1–3 years of GLP-1 drug use (Bezin 2023); Scandinavian cohort: 1.33 versus 1.46 cases per 10,000 person-years, HR 0.93 (95% CI 0.66 to 1.31) (Pasternak 2024).

Pulmonary Aspiration During Anesthesia

Slowed stomach emptying can leave food in the stomach despite fasting, raising the risk of aspiration (inhaling stomach contents into the lungs) under sedation; the label reports rare postmarketing cases (Wegovy FDA label). A class-level cohort (indirect: mixed GLP-1 drugs) found more retained stomach contents (Wu 2024).

Magnitude: Retained gastric contents in 19% versus 5% of endoscopies, adjusted OR 5.8 (95% CI 1.7 to 19.3) (Wu 2024).

Depression and Suicidal Thoughts ⚠️ Conflicted

The US label carried a warning on suicidal behavior and ideation until its removal in February 2026 (Wegovy FDA label). Pooled STEP trial data found no increase in depression or suicidal ideation (Wadden 2024). Net reading: controlled data show no excess psychiatric risk.

Magnitude: Suicidal ideation or behavior in 1% or fewer of participants, no different from placebo; PHQ-9 (a 0–27 depression questionnaire) score 0.56 points lower than placebo (95% CI −0.81 to −0.32) (Wadden 2024).

Serious Hypersensitivity Reactions

Anaphylaxis (severe allergic reaction) and angioedema (rapid deep-skin swelling) have been reported after marketing, and prior serious hypersensitivity is a label contraindication (Wegovy FDA label). An allergy-unit case series described hypersensitivity reactions to semaglutide and liraglutide (Barroso 2024). Frequency is unknown.

Magnitude: Not quantified in available studies. Only postmarketing reports and case series exist, which give no rate and no comparison group.

Nutritional Deficiencies, Including Wernicke Encephalopathy

Eating substantially less, plus vomiting, can deplete protein, vitamin D, vitamin B12 and thiamine (vitamin B1). A GLP-1 drug claims study found frequent new deficiency diagnoses (indirect: class-level, not semaglutide-specific) (Butsch 2025). Case reports describe Wernicke encephalopathy (thiamine-deficiency brain injury), with disproportionate reporting for semaglutide (Gras 2025).

Magnitude: In a matched comparison, nutritional deficiencies were newly diagnosed within 12 months in 18.6% of GLP-1 drug plus metformin users versus 16.5% of metformin-only users (Butsch 2025); 19 Wernicke encephalopathy cases reported, no rate given, no control group (Gras 2025).

Speculative 🟨

No risk is graded Speculative: every listed risk has human data (trials, observational studies or case reports), so none rests on animal, in-vitro or mechanistic evidence alone.

Risk-Modifying Factors

  • Genetics: Germline mutations in RET (a gene whose mutations cause MEN 2, multiple endocrine neoplasia type 2, an inherited tumor syndrome) and a family history of MTC (medullary thyroid carcinoma, a rare thyroid cancer) define the contraindicated group (Wegovy FDA label).
  • Side-effect genetics: GLP1R variants were associated with nausea or vomiting on GLP-1 drugs in a self-reported genome-wide study (Su 2026); the finding is class-level (indirect: not semaglutide-specific) and not yet used clinically.
  • Baseline biomarkers: Low baseline lean mass, high HbA1c with existing retinopathy, reduced eGFR and known gallstones raise the relevance of lean-mass loss, retinopathy worsening, acute kidney injury and gallbladder disease, respectively.
  • Sex: Hair loss appears to affect women disproportionately (Gupta 2026), and hip and pelvic fractures were more frequent in women in SELECT (Wegovy FDA label); women planning pregnancy face a stop requirement of at least two months before conception (Wegovy FDA label).
  • Pre-existing conditions: Gastroparesis (delayed stomach emptying), prior pancreatitis, gallbladder disease and diabetic retinopathy amplify the corresponding risks (Marso 2016, Wegovy FDA label); prior NAION and eating disorders plausibly do too (inferred from mechanism).
  • Age: Adults over 65 face greater consequences from lean-mass loss, dehydration and falls, and few adults over 75 were studied (Wegovy FDA label).
  • Dose: The 7.2 mg dose produced more gastrointestinal events and dysesthesia than 2.4 mg (Wharton 2025).

Key Interactions & Contraindications

Documented interactions:

  • Insulin and sulfonylureas (glipizide, glimepiride, glyburide): Higher risk of hypoglycemia, including severe episodes; the label advises considering lower insulin or sulfonylurea doses at initiation and monitoring glucose (Wegovy FDA label).
  • Levothyroxine with oral semaglutide: Total thyroxine exposure rose 33% when taken with oral semaglutide (Hauge 2021); thyroid-stimulating hormone (TSH) monitoring after starting or changing doses manages the risk of over-replacement.
  • Other tablets taken with oral semaglutide: Co-administered tablets reduced semaglutide exposure by 34% (Hauge 2021); the label specifies taking it alone with up to 4 ounces of water and waiting 30 minutes (Wegovy FDA label).
  • Warfarin, metformin, atorvastatin, digoxin: No clinically relevant pharmacokinetic interaction found, and no change in warfarin’s INR (a blood-clotting time measure), with injectable semaglutide (Hausner 2017); the label still advises monitoring narrow-margin oral drugs (Wegovy FDA label).
  • Combined oral contraceptives (ethinylestradiol/levonorgestrel): No clinically relevant interaction found: contraceptive exposure was not reduced, though levonorgestrel exposure rose 20% (Kapitza 2015).
  • Lisinopril, warfarin, digoxin and metformin with oral semaglutide: No change in lisinopril, warfarin or digoxin exposure; metformin exposure rose 32%, judged not clinically relevant given its wide safety margin (Bækdal 2019).
  • Rosuvastatin and furosemide with oral semaglutide: Exposure rose 41% and 28%, respectively, judged not clinically relevant (Jordy 2021); monitoring for statin (cholesterol-lowering drug) side effects such as muscle pain after starting tablets is the mitigation.
  • Alectinib (a lung-cancer drug): One semaglutide dose reduced alectinib exposure 32%, likely through lower food intake, risking loss of anticancer effect (Heersche 2025); alectinib blood-level monitoring is the mitigation.
  • Lithium (a mood stabilizer): Lithium levels rose to toxicity in two of three patients after semaglutide was started, possibly through dehydration or altered kidney clearance (Al-Soleiti 2025); lithium-level and kidney-function checks before and during treatment are the mitigation.
  • Omeprazole and paracetamol (acetaminophen; over the counter): No clinically relevant interaction found: omeprazole raised oral semaglutide exposure 13%, not significantly (Bækdal 2018), and semaglutide slowed paracetamol absorption without clinical relevance (Langeskov 2022); no dose adjustment is expected.
  • Blood-pressure-lowering drugs (amlodipine, losartan): Hypotension and orthostatic hypotension (a blood-pressure drop on standing) occurred more often in trial participants also taking these drugs (Wegovy FDA label); antihypertensive doses were reduced more often with semaglutide (Tchang 2025), so home blood-pressure checks guide dose review.
  • Other GLP-1 receptor agonists or semaglutide products (liraglutide, dulaglutide, tirzepatide): Avoid; co-use is not recommended by the label because effects and side effects duplicate (Wegovy FDA label).

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Loperamide (over the counter) and opioid-containing cough or antidiarrheal products (codeine, diphenoxylate): Additive slowing of gut transit may worsen constipation or contribute to ileus; inferred from shared effects on gastrointestinal motility. Limiting use during dose escalation reduces the risk.
  • NSAIDs (nonsteroidal anti-inflammatory drugs such as ibuprofen and naproxen, over the counter): During vomiting or diarrhea, additive strain on kidney blood flow may raise acute kidney injury risk; inferred from volume depletion plus NSAID kidney effects. Pausing NSAIDs during dehydration is the mitigation.
  • Glucose-lowering supplements (berberine, chromium, cinnamon extract): Additive glucose lowering may increase hypoglycemia in people also taking insulin or sulfonylureas; inferred from additive glycemic effects. Glucose checks when adding them mitigate this.
  • Fiber supplements (psyllium, glucomannan): Additive fullness and slowed gastric emptying may worsen nausea and bloating; inferred from shared effects on stomach emptying. Gradual introduction limits symptoms.
  • Blood-pressure-lowering supplements (beetroot nitrate, garlic extract): Additive lowering alongside weight loss and fluid loss may cause dizziness or low blood pressure; inferred from additive blood-pressure effects. Home blood-pressure checks guide continued use.
  • Alcohol: Additive hypoglycemia in insulin users and a possible additive pancreatitis risk; inferred from overlapping metabolic and pancreatic effects. Moderating intake reduces both.
  • Very-low-calorie diets or prolonged fasting: Added calorie deficit may accelerate lean-mass loss and gallstone formation; inferred from mechanism. Adequate protein and gradual weight loss mitigate this.

Populations who should avoid Semaglutide:

  • Personal or family history of MTC, or MEN 2: contraindicated (Wegovy FDA label).
  • Prior serious hypersensitivity, including anaphylaxis (severe allergic reaction) or angioedema (rapid deep-skin swelling), to semaglutide or its inactive ingredients: contraindicated (Wegovy FDA label).
  • Pregnancy, or pregnancy planned within 2 months: may cause fetal harm (Wegovy FDA label).
  • Breastfeeding while using semaglutide tablets: not recommended because SNAC passes into milk (Wegovy FDA label).
  • Severe gastroparesis: not recommended (Wegovy FDA label).
  • Confirmed NAION during treatment: treatment to be stopped (EMA safety committee review).
  • Type 1 diabetes: use has not been evaluated (Wegovy FDA label).
  • Prior pancreatitis: inferred from the label’s direction to stop if pancreatitis is suspected; no trial data in this group (Wegovy FDA label).
  • Underweight (body-mass index below 18.5) or active eating disorder: inferred from appetite suppression and malnutrition risk; no human data.

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Slow titration (gradual dose escalation): The label schedule starts at 0.25 mg weekly and steps up every 4 weeks, with escalation delayed by 4 weeks if poorly tolerated (Wegovy FDA label); reduces gastrointestinal adverse events.
  • Lowest effective maintenance dose: Staying at 1.7 or 2.4 mg rather than 7.2 mg when goals are met limits gastrointestinal events and dysesthesia (Wharton 2025).
  • Meal and fluid habits: Smaller, lower-fat meals, stopping at first fullness, and 2–3 L of fluid daily reduce nausea and prevent dehydration-related acute kidney injury.
  • Protein and resistance training: 1.2–1.6 g of protein per kg body weight daily plus resistance training 2–3 times weekly to limit lean-mass loss.
  • Body-composition tracking: DXA at baseline and every 6–12 months during active weight loss detects excessive lean-mass loss early.
  • Eye safeguards: A retinal exam before starting in people with diabetic retinopathy; sudden vision loss prompts urgent evaluation and, if NAION is confirmed, stopping (EMA safety committee review).
  • Procedure planning: Informing the anesthesia team and a 24-hour clear-liquid diet before procedures reduce aspiration risk, per guidance from societies whose members perform these procedures (Kindel 2025).
  • Gallbladder vigilance: Gradual weight loss and prompt evaluation of right-upper abdominal pain, fever or jaundice (yellowing of the skin) address gallstone complications (Wegovy FDA label).
  • Pancreatitis stop rule: The label directs stopping treatment if persistent severe abdominal pain, sometimes radiating to the back, suggests pancreatitis (Wegovy FDA label).
  • Hypoglycemia prevention: Lower insulin or sulfonylurea doses at initiation, with glucose checks, prevent hypoglycemia (Wegovy FDA label).
  • Planned exit: A maintenance plan before stopping, with intensified diet and exercise, limits weight and metabolic rebound.
  • Pregnancy planning: Stopping at least 2 months before planned conception avoids fetal exposure (Wegovy FDA label).
  • Approved products only: FDA-approved pens and tablets avoid the dosing errors reported with compounded multi-dose vials (FDA compounding statement).

Therapeutic Protocol

Doses below are cited to their sources; timing, titration pace and other parameters without a citation reflect common practice.

  • Weight and cardiovascular protocol (Wegovy injection): 0.25 mg weekly for 4 weeks, then 0.5, 1 and 1.7 mg in 4-week steps; maintenance 2.4 mg (or 1.7 mg) weekly, up to 7.2 mg for further weight loss (Wegovy FDA label).
  • High-dose option: 7.2 mg weekly produced 18.7% weight loss versus 15.6% with 2.4 mg, at the cost of more side effects (Wharton 2025).
  • Oral weight protocol (Wegovy tablets): 1.5 mg daily for 30 days, then 4 mg and 9 mg, with 25 mg daily maintenance (Wegovy FDA label).
  • Diabetes and kidney protocol (Ozempic): 0.25 mg weekly for 4 weeks, then 0.5 mg; 1 mg for kidney protection, up to 2 mg for glucose control (Ozempic FDA label).
  • Lower-dose longevity approach (no outcome trials): Peter Attia notes the mouse lifespan dose approximated human exposure between diabetes doses and weight-loss doses (Attia article); diabetes doses are 0.5–1 mg weekly (Ozempic FDA label).
  • Time of day: Injections at any time of day on the same weekday, with or without meals; tablets on waking with an empty stomach, 30 minutes before food or drink (Wegovy FDA label).
  • Half-life: About one week, which allows weekly injection; the drug persists 5–7 weeks after the last dose (Wegovy FDA label).
  • Single versus split dosing: The weekly injection is a single dose, never split; tablets are once daily. After two or more missed injections, titration restarts at a lower dose (Wegovy FDA label).
  • Genetics: No pharmacogenetic dosing guidance exists; semaglutide bypasses cytochrome P450 metabolism, so common drug-metabolism variants are irrelevant, per a pharmacokinetic review (Yang 2024). RET mutations (MEN 2) exclude use.
  • Sex: No sex-specific dosing, though women lost weight faster than men (Phan 2025); for women who may become pregnant, the label specifies stopping at least 2 months before conception (Wegovy FDA label).
  • Age: No age-based dose adjustment; older adults often use slower titration and lower maintenance doses to protect lean mass and hydration.
  • Baseline biomarkers: Higher HbA1c, weight or blood pressure supports full maintenance doses; near-normal baselines favor lower doses, since absolute benefit scales with baseline values.
  • Pre-existing conditions: No dose adjustment for kidney or liver impairment, per a pharmacokinetic review (Yang 2024); insulin or sulfonylurea doses may need reduction (Wegovy FDA label).

Discontinuation & Cycling

  • Lifelong versus short-term: Benefits last only while treatment continues; weight and cardiometabolic gains largely reverse within a year of stopping (Wilding 2022), so semaglutide is generally used long term.
  • Withdrawal effects: No physiological withdrawal syndrome; appetite and food cravings return gradually as the drug clears over 5–7 weeks (Wegovy FDA label).
  • Tapering: No validated taper exists; common practice steps down through lower doses over months alongside intensified diet and resistance training, though evidence that tapering prevents regain is lacking.
  • Cycling: Not studied; no source supports cycling for maintaining efficacy, and interruptions of 2 or more weekly doses require re-titration from a lower dose (Wegovy FDA label).
  • Planned interruptions: Stopping at least 2 months before conception is required (Wegovy FDA label); for most procedures, continuation with a pre-procedure liquid diet is suggested by guidance from societies whose members perform these procedures (Kindel 2025).

Sourcing and Quality

  • FDA-approved products: Ozempic, Wegovy and Rybelsus from Novo Nordisk are FDA-approved semaglutide products, manufactured as prefilled pens or tablets under FDA oversight (Wegovy FDA label, Ozempic FDA label).
  • Compounded semaglutide: Not reviewed by the FDA for safety, effectiveness or quality; FDA reports dosing errors with compounded multi-dose vials, some requiring hospitalization (FDA compounding statement).
  • Salt forms: Semaglutide sodium and semaglutide acetate are different active ingredients from those in approved products, and the FDA lacks data on their equivalence (FDA compounding statement).
  • Research-labeled and counterfeit products: FDA has warned against semaglutide sold “for research purposes” and against counterfeit Ozempic in the US (FDA compounding statement).
  • What to look for: A prescription after medical screening, a state-licensed pharmacy, intact packaging with instructions, and prices that are not implausibly low (FDA compounding statement).
  • Formulation differences: Injection and tablets are not interchangeable milligram for milligram; tablets contain the absorption enhancer SNAC (Wegovy FDA label).

Practical Considerations

  • Time to effect: Appetite falls within days; most weight loss accrues over 12–16 months, as in STEP 1 (Wilding 2021); cardiovascular benefit in SELECT emerged over years of follow-up (Lincoff 2023).
  • Common pitfalls: Escalating too quickly, eating too little protein, skipping resistance training, insufficient fluid intake, stopping without a maintenance plan, and buying unregulated compounded or “research” products (FDA compounding statement).
  • Regulatory status: Prescription-only; approved for type 2 diabetes, chronic weight management, cardiovascular risk reduction, diabetic kidney disease and MASH (Wegovy FDA label, Ozempic FDA label); use for aging in lean adults is off-label.
  • Cost and access: Expensive without insurance coverage. Because payers bear high long-term costs relative to cheaper lifestyle programs, they have a structural incentive to restrict coverage, a potential source of bias in coverage policy, guideline formation and research funding.
  • Funding of the evidence: Nearly all outcome trials were funded by Novo Nordisk, which also employs co-authors; independent meta-analyses largely agree with the trial findings (Sillassen 2025).

Interaction with Foundational Habits

  • Sleep: Indirect and generally neutral to supportive: no direct effect on sleep architecture is known, weight loss may ease obesity-related sleep-disordered breathing, but nausea and reflux early in titration can disrupt sleep; avoiding large late meals helps.
  • Nutrition: Direct and appetite-blunting: lower intake makes protein (1.2–1.6 g/kg daily), fiber, fluids and micronutrients such as vitamin B12, iron and vitamin D a priority; large, high-fat meals worsen nausea, and alcohol intake may fall (Hendershot 2025).
  • Exercise: Potentiating when combined with resistance training, which counters lean-mass loss; walking capacity improved in a heart failure trial (Kosiborod 2023). Training while dehydrated or nauseated during titration raises dizziness risk, which sessions timed away from peak symptoms avoid.
  • Stress management: Indirect: reduced food-reward signaling may blunt stress-driven eating, and no effect on cortisol is known; depression scores did not worsen in pooled trials (Wadden 2024). Mindfulness and sleep routines complement appetite changes.

Monitoring Protocol & Defining Success

Baseline testing before starting covers weight, waist circumference, body composition by DXA, blood pressure, resting heart rate, HbA1c, fasting glucose, creatinine with eGFR, hs-CRP (high-sensitivity CRP) and, for oral-tablet users taking levothyroxine, TSH. For people with diabetic retinopathy, a baseline eye exam supports the monitoring the label advises (Wegovy FDA label), given the retinopathy complications seen in SUSTAIN-6 (Marso 2016), and a personal or family history of MTC or MEN 2 is excluded; routine calcitonin testing is of uncertain value (Wegovy FDA label).

Ongoing monitoring follows this cadence: weight, side effects and glucose (if on insulin or sulfonylureas) every 4 weeks during titration; labs at 3 months, then every 6–12 months; DXA every 6–12 months during active weight loss; kidney function promptly after severe vomiting or diarrhea.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Body weight and waist circumference No established target; track percentage change from own baseline Expected to change: primary efficacy marker Same scale, morning, fasting; waist at navel level
Lean mass (DXA) No established target; track lean-mass share of total weight lost Safety check: excessive lean loss prompts protein, training or dose review Same scanner each time; pair with grip strength
HbA1c 4.0–5.6% (standard reference range) Expected to change No fasting needed; reflects about 3 months; anemia distorts results
Fasting glucose 70–99 mg/dL (standard reference range) Safety check: hypoglycemia with insulin or sulfonylureas 8-hour fast; home glucose checks during dose changes
Blood pressure Below 130/80 mm Hg (ACC/AHA guideline target, Whelton 2018) Expected to change; safety check if on blood-pressure medicines Source: Whelton 2018, ACC/AHA (American College of Cardiology/American Heart Association), societies whose members treat hypertension; conventional reference range: below 120/80 mm Hg; seated, rested, averaged readings
Resting heart rate 60–100 beats per minute (standard reference range) Safety check: label reports increases Seated after 5 minutes of rest; same time of day
Creatinine with eGFR Creatinine 0.59–1.04 mg/dL (women), 0.74–1.35 mg/dL (men) (standard reference range) Safety check: dehydration-related acute kidney injury Recheck after vomiting or diarrhea; avoid testing after heavy exercise
hs-CRP No established target; track change from own baseline Expected to change: fell 43.5% versus 7.3% with placebo in STEP-HFpEF (Kosiborod 2023) Avoid testing during acute illness or after intense exercise
TSH (levothyroxine users on oral tablets) 0.4–4.0 mIU/L (standard reference range) Safety check: oral semaglutide raises thyroxine exposure Recheck 6–8 weeks after starting; morning, before levothyroxine

Qualitative markers:

  • Appetite control and fewer intrusive thoughts about food
  • Gastrointestinal tolerance (nausea, constipation, reflux)
  • Energy, strength and exercise performance
  • Mood, cravings and alcohol intake
  • Vision changes, with sudden loss evaluated urgently
  • Hair shedding

Emerging Research

  • ASCEND PLUS (oral semaglutide for primary prevention): NCT05441267, University of Oxford, phase 4, 21,296 people with type 2 diabetes, primary endpoint major adverse cardiovascular events (primary completion 2028). A positive result would extend cardiovascular benefit to primary prevention; a null result would confine it to established disease.
  • ESSENCE part 2 (liver outcomes): NCT04822181, phase 3, 1,205 participants with MASH, cirrhosis-free survival through 2029. A positive result would confirm that biopsy gains prevent cirrhosis; a null result would downgrade the liver benefit.
  • FOCUS (retinopathy safety): NCT03811561, phase 3, 1,500 people with type 2 diabetes, primary endpoint three-step retinopathy progression (completion 2027). More progression would upgrade the retinopathy risk; a null result would confirm meta-analytic reassurance.
  • STAR (alcohol reduction): NCT06015893, National Institute on Drug Abuse, phase 2, 63 participants, primary endpoint alcohol drinking (completion 2027). A positive result would strengthen the alcohol benefit; a null result would weaken it.
  • SOBER II (bone turnover): NCT06050577, Odense University Hospital, phase 2, 64 participants, primary endpoint P1NP (procollagen type 1 N-terminal propeptide, a bone-formation marker). Reduced bone formation would add a bone risk; no change would reassure.
  • Muscle and heart mass study: NCT07272837, University of Alberta, 50 participants, skeletal and cardiac muscle mass (completion 2028). Greater-than-expected muscle loss would strengthen the lean-mass risk; preservation would weaken it.
  • EVOKE and EVOKE+ (completed): NCT04777396 and NCT04777409, completed January 2026 (no registry results posted); published results in 3,808 participants showed no slowing of early Alzheimer’s disease (dementia-rating score difference −0.08 and 0.10 points versus placebo) (Cummings 2026).
  • Aging biology: Human trials with validated aging endpoints are needed to test the mouse lifespan extension (Feng 2026) and the slower epigenetic clocks (Corley 2026); negative results would remove the aging rationale.
  • Safety signals and exit strategies: Studies that confirm or refute the claims-data NAION signal (Tesfaye 2026) and trials of strategies against the rebound documented after discontinuation (Tzang 2025) could reshape the risk-benefit balance in either direction.

Conclusion

Semaglutide is a weekly injection or daily tablet that copies a gut hormone controlling appetite and blood sugar. For adults carrying excess weight, diabetes, or existing heart or kidney disease, the evidence is unusually strong: large, long trials show substantial and lasting weight loss, fewer heart attacks and strokes, slower kidney decline and longer survival, and independent combined analyses agree.

The picture is thinner for lean, healthy adults seeking more years of healthy life. No trial has measured heart attacks, strokes or deaths in that group, and the case that it slows aging itself rests on one mouse study and early blood-marker data. Hopes that it protects against dementia faded when trials in early Alzheimer’s disease showed no benefit.

The costs are real. Digestive side effects are common, part of the weight lost is muscle, gallstones become more frequent, and a rare optic-nerve stroke causing vision loss has been linked to the drug. Benefits fade and weight returns after stopping, which makes this a long-term commitment rather than a short course. Protein intake, strength training and slow dose increases shape how much muscle is kept.

Most of the evidence comes from trials paid for by the manufacturer, Novo Nordisk, although independent analyses largely agree with them. Overall, semaglutide’s value for a longer, healthier life is well established where weight-related disease is present and remains uncertain where it is not.

Top - Benefits - Risks - Protocol